ankyrin repeat


Also found in: Wikipedia.

ankyrin repeat

A short repetitive sequence of amino acids consisting of a beta strand followed by two alpha helices and a beta strand. The beta strands on adjacent ankyrin repeats combine to form a short antiparallel beta sheet. Ankyrin repeats were first identified in ankyrin, which tethers different proteins (e.g., nuclear and cytoplasmic proteins), helping regulate gene expression and embryonic development.
References in periodicals archive ?
Two SNPs were located on a narrow region of chromosome 4 (from 15.59 Mb to 16.04 Mb), and the nearest genes were inhibitor of apoptosis protein 3 (IAP3) and sosondowah ankyrin repeat domain family member D (SOWAHD).
However, it was proven that the SNP rs1800497 is a part of the exon 8 of ankyrin repeat and protein kinase domain-containing protein 1 (ANKK1) gene [4].
DARPins (Designed Ankyrin Repeat Proteins) are artificial proteins that recognize and bind antigens.
Several scaffolds, such as affibody molecules, knottins, designed ankyrin repeat proteins (DARPins), adnectins, and ADAPTs, have been preclinically evaluated for radionuclide molecular imaging and demonstrated capacity of imaging molecular targets in vivo at the day of injection [14].
Background: The Notch-regulated ankyrin repeat protein (NRARP) is recently found to promote proliferation of breast cancer cells.
The active ingredient, which comprises several DARPins (designed ankyrin repeat proteins), is also easy to produce.
The Z-disk proteins include [alpha]-actinin 2, cardiac ankyrin repeat protein, muscle LIM protein, LIM binding domain 3, myozenin 2, telethonin, and vinculin/metavinculin.
The drug MP0112 is a designated ankyrin repeat protein that selectively binds VEGF-A isoforms.
"Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors," Journal of Virology 87(10): 5868-5881.
The Coxiella burnetii ankyrin repeat domain-containing protein family is heterogeneous.
Biopharmaceutical company Cubist Pharmaceuticals Inc (NASDAQ:CBST) and Hydra Biosciences Inc announced on Tuesday the joint proposal to commence a Phase 1 clinical study for a small molecule antagonist of the human Transient Receptor Potential Ankyrin repeat 1 (TRPA1) ion channel.
EPH receptor A5, RAB17, SH3 and multiple ankyrin repeat domains 2, and GHRL are related to regulation of synapse assembly [32-34].